
==== Front
Intensive Care Med Exp
Intensive Care Med Exp
Intensive Care Medicine Experimental
2197-425X
Springer International Publishing Cham

672
10.1186/s40635-024-00672-1
Reviews
Advancements in understanding the mechanisms of lung–kidney crosstalk
Mendes Renata de Souza 12
Silva Pedro Leme 3
Robba Chiara 45
Battaglini Denise 45
Lopes-Pacheco Miquéias 6
Caruso-Neves Celso 7
http://orcid.org/0000-0003-1412-7136
Rocco Patricia R. M. prmrocco@gmail.com

3
1 https://ror.org/0198v2949 grid.412211.5 0000 0004 4687 5267 Department of Nephrology, State University of Rio de Janeiro, Rio de Janeiro, Brazil
2 https://ror.org/03490as77 grid.8536.8 0000 0001 2294 473X Department of Nephrology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
3 grid.8536.8 0000 0001 2294 473X Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha Do Fundão, Rio de Janeiro, RJ 21941-902 Brazil
4 grid.410345.7 0000 0004 1756 7871 IRCCS Policlinico San Martino, Genoa, Italy
5 https://ror.org/0107c5v14 grid.5606.5 0000 0001 2151 3065 Dipertimento di Scienze Chirurgiche Diagnostiche e Integrate, Policlinico San Martino, IRCCS Per l’Oncologia e Neuroscienze, Università degli Studi di Genova, Genoa, Italy
6 grid.189967.8 0000 0001 0941 6502 Department of Pediatrics, Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, GA USA
7 grid.8536.8 0000 0001 2294 473X Laboratory of Biochemistry and Cellular Biology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
16 9 2024
16 9 2024
12 2024
12 8122 6 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This narrative review delves into the intricate interplay between the lungs and the kidneys, with a focus on elucidating the pathogenesis of diseases influenced by immunological factors, acid–base regulation, and blood gas disturbances, as well as assessing the effects of various therapeutic modalities on these interactions. Key disorders, such as anti-glomerular basement membrane (anti-GBM) disease, the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and Anti-neutrophil Cytoplasmic Antibodies (ANCA) associated vasculitis (AAV), are also examined to shed light on their underlying mechanisms. This review also explores the relationship between acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI), emphasizing how inflammatory mediators can lead to systemic damage and impact multiple organs. In ARDS, fluid overload exacerbates pulmonary edema, while imbalances in blood volume, such as hypovolemia or hypervolemia, can precipitate renal dysfunction. The review highlights how mechanical ventilation strategies can compromise renal blood flow, trigger systemic inflammation, and induce hemodynamic and neurohormonal alterations, all contributing to lung and kidney damage. The impact of extracorporeal membrane oxygenation (ECMO) on lung–kidney interactions is evaluated, highlighting its role in severe respiratory failure and its renal implications. Emerging therapies, such as mesenchymal stem cells and extracellular vesicles, are discussed as promising avenues to mitigate organ damage and enhance outcomes in critically ill patients. Overall, this review offers a nuanced exploration of lung–kidney dynamics, bridging historical insights with contemporary perspectives. It underscores the clinical significance of these interactions in critically ill patients and advocates for integrated management approaches to optimize patient outcomes.

Keywords

Acute kidney injury
Acute respiratory distress syndrome
Inflammation
Extracorporeal membrane oxygenation
Kidney
Lung
http://dx.doi.org/10.13039/501100003593 Conselho Nacional de Desenvolvimento Científico e Tecnológico 408124/2021-0 Rocco Patricia R. M. http://dx.doi.org/10.13039/501100004586 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.181/2020 Rocco Patricia R. M. issue-copyright-statement© European Society of Intensive Care Medicine and Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

Inter-organ crosstalk represents a fundamental mechanism of bilateral communication, essential for maintaining physiological homeostasis through intricate cellular interactions, immune responses, and neurohormonal regulation [1]. However, under pathological conditions, this intricate interplay can precipitate or exacerbate primary injury in one or multiple organs [2].

Recent research has focused on the intricate interactions between lungs and kidneys, particularly in pulmonary–renal syndromes. These syndromes arise from various factors, including immunological triggers, such as anti-glomerular basement membrane (anti-GBM) antibody disease [3], the syndrome of inappropriate antidiuretic hormone secretion (SIADH) [4], and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [5]. Additionally, disturbances in fluid regulation, acid–base balance, and blood gas dynamics, such as hypoxemia or hypercapnia, can lead to tissue injury in both the respiratory and renal systems. [6].

Kidney disorders can instigate metabolic acidosis and fluid retention, activating the lung–buffer interaction and potentially fostering pulmonary damage by hindering the clearance of inflammatory mediators [7]. Moreover, alterations in renal hemodynamics and neurohormonal responses can further contribute to lung injury. Conversely, lung pathologies, particularly those requiring mechanical ventilation, can trigger systemic inflammatory responses that increase the risk of kidney injury [7].

Extracorporeal interventions, such as renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO), significantly influence lung–kidney crosstalk dynamics. While RRT can influence pulmonary function, ECMO may have adverse effects on renal function [8].

Emerging therapies, such as mesenchymal stem cells and extracellular vesicles (EVs), show promise in modulating lung–kidney interactions. EVs, key players in intercellular communication, may play a critical role in the pathogenesis of diseases affecting both organs [9, 10].

This narrative review seeks to elucidate the physiological interactions between lungs and kidneys, explore specific disorders, such as anti-GBM disease, SIADH, and AAV, and assess the impact of therapeutic modalities including mechanical ventilation, ECMO, and RRT. By deepening our understanding of these interactions, we aim to underscore their implications for overall body homeostasis and improve clinical outcomes for patients with related conditions.

Physiologic interactions between lungs and kidneys

The lungs regulate blood pH by controlling CO₂ levels, adjusting breathing to manage these levels, which directly influences pH. The kidneys contribute to acid–base balance by excreting hydrogen ions, reabsorbing, and producing bicarbonate. Additionally, the lungs affect fluid balance through respiratory water loss, which can be exacerbated by hyperventilation. The kidneys maintain fluid balance by filtering blood, reabsorbing essentials, and excreting excess water and electrolytes [11]. The lungs also produce ACE, influencing blood pressure, while the kidneys release hormones like erythropoietin and renin, critical for blood pressure regulation and red blood cell production [12].

Classic interactions between kidneys and lungs

Classic interactions between kidneys and lungs encompass various factors, including immunologic conditions like anti-GBM disease, disturbances in water regulation seen in SIADH, AAV, as well as disruptions in acid–base balance and blood gas levels.

Anti-glomerular basement membrane disease

Anti-GBM disease exemplifies the severe impact of immune overactivation on both respiratory and renal systems. This rare condition is marked by antibodies, particularly IgG1 and IgG3, targeting antigens in the basement membrane, including the alpha-3 domain of type IV collagen, peroxidasin, and laminin-521. These antibodies attack glomerular capillaries in the kidneys and alveolar capillaries in the lungs, leading to crescent glomerulonephritis and pulmonary hemorrhage in about 50% of cases [3].

Genetic factors, notably specific HLA types, influence susceptibility to anti-GBM disease. HLA-DR1 and DR7 offer some protection, while HLA-DR15 and DR4 increase susceptibility by exposing epitopes that lead to immune dysregulation [13]. Epigenetic and environmental factors, such as pulmonary infections (including COVID-19), smoking, exposure to hydrocarbon solvents, and lung cancer, further elevate the risk by triggering or worsening the immune response [14].

Understanding the complex interplay between genetic susceptibility, environmental triggers, and immune dysregulation is crucial for managing and treating anti-GBM disease. Further research into these areas may provide insights into the mechanisms of the disease and potential therapeutic targets.

Syndrome of inappropriate antidiuretic hormone secretion

Vasopressin, or antidiuretic hormone (ADH), is secreted by the hypothalamus and regulates osmotic balance, blood pressure, and kidney function. Under normal conditions, vasopressin levels rise in response to elevated plasma osmolarity or reduced blood volume, prompting water reabsorption in the kidneys to maintain homeostasis [15]. However, in conditions like pneumonia, asthma, atelectasis, respiratory failure, mechanical ventilation, neoplasia, and pneumothorax, vasopressin production can increase inappropriately, independent of osmolarity or blood volume, leading to imbalances in fluid regulation [15].

Anti-neutrophil cytoplasmic antibodies-associated vasculitis

Anti-neutrophil cytoplasmic antibody-associated vasculitis involves both lungs and kidneys, leading to significant morbidity and mortality. The pathogenesis of AAV is driven by a complex interplay of immune responses, endothelial damage, and inflammation. In AAV, the immune system produces ANCAs that target proteins like myeloperoxidase or proteinase 3 on neutrophils. When ANCAs bind to these proteins, they activate neutrophils, which then release reactive oxygen species and proteolytic enzymes, causing tissue damage. This process damages endothelial cells, increases vascular permeability, and triggers inflammation, marked by the release of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6. This leads to vasculitis, granuloma formation, and further tissue injury in the lungs and kidneys. The complement system, especially the alternative pathway, also plays a critical role in mediating inflammation and tissue injury in AAV [15].

In the lungs, AAV can cause diffuse alveolar hemorrhage due to damage to pulmonary capillaries, while chronic inflammation may lead to interstitial lung disease with fibrosis and reduced lung function. In the kidneys, similar immune mechanisms result in glomerulonephritis and crescent glomerulonephritis, leading to progressive renal dysfunction.

Disruption in acid–base balance

Acid–base balance is tightly regulated by the lungs and kidneys to maintain plasma pH within the narrow range of 7.35–7.45, essential for optimal cellular function. The lungs manage pH by eliminating carbon dioxide, while the kidneys maintain balance by reabsorbing bicarbonate and generating new bicarbonate through titratable acidity and ammonia excretion. This interaction becomes critical in patients with severe lung disease, especially those on mechanical ventilation. Improper ventilator settings can exacerbate acid–base imbalances, placing additional strain on the kidneys [16].

Bicarbonate (HCO3−) and arterial partial pressure of carbon dioxide (PaCO2) are key in this regulation, with bicarbonate directly and PaCO2 inversely affecting pH. In chronic conditions like chronic obstructive pulmonary disease (COPD), where CO2 retention is common, the kidneys' ability to regenerate bicarbonate is vital. However, patients with renal dysfunction or advanced chronic kidney disease may struggle to maintain pH balance, leading to respiratory acidemia and increased mortality risk [17].

COPD is often accompanied by malnutrition, muscle wasting, and renal issues, which further compromise acid–base regulation. Diuretic use in COPD management can also impact renal function and acid–base balance. Effective management of chronic hypercapnia in COPD requires a comprehensive approach, including optimizing ventilator settings, monitoring medications, and ensuring adequate nutritional support [18].

In summary, lungs and kidneys work together to maintain pH balance, and dysfunction in either system can severely disrupt this delicate equilibrium, particularly in patients with chronic lung disease [19].

Blood gas disturbances

Renal blood flow is regulated by factors like the myogenic reflex and tubuloglomerular feedback [20], making kidneys highly sensitive to hypoxic injuries due to their high oxygen demand per gram of tissue [21]. This demand is influenced by several factors, including glomerular–tubular balance, sodium reabsorption, and metabolic activity. In systemic hypercapnia, the increased need for bicarbonate reabsorption and regeneration affects the GFR [22]. Neurohormonal regulators, including angiotensin II, nitric oxide, and adrenergic nerves, are crucial for balancing oxygen supply and demand. If vasodilatory responses fail, compensatory mechanisms may not suffice, potentially leading to renal injury [16].

Lung diseases that alter blood gas values, such as hypoxemia or hypercapnia, can significantly impact renal hemodynamics. Acute hypercapnia reduces renal blood flow, a condition more pronounced in patients with exacerbated COPD [23, 24]. This reduction is caused by both direct renal vasoconstriction and indirect mechanisms, including systemic vasodilation and baroreceptor inactivation, leading to norepinephrine release and further reduced renal blood flow [23, 24]. Neurogenic mechanisms play a key role in this process, as demonstrated by a study showing that denervated kidneys do not exhibit the same blood flow reduction [25].

Hypercapnia can also increase pulmonary vascular resistance, potentially leading to right ventricular dysfunction [26]. Chronic respiratory disorders often result in fluid retention, pulmonary edema, and congestion, associated with reduced renal blood flow and impaired sodium excretion [24].

Hypoxemia also affects renal blood flow, possibly through a reflex mechanism involving sympathetic nerves and chemoreceptor stimulation. The role of nitric oxide (NO) in this response is suggested, as COPD patients often show a lack of response to L-arginine, indicating potential deficiencies in NO-mediated vasodilation [27].

In summary, disruptions in blood gas levels due to lung disease can profoundly impact renal hemodynamics, with hypercapnia and hypoxemia leading to reduced renal blood flow and potential renal injury.

The role of ARDS in the development of AKI

Acute kidney injury occurs in approximately 30% of ARDS patients, associating with increased mortality rates and prolonged hospital stays [28]. Nearly half of these individuals also require RRT [29]. While ARDS primarily impairs kidney function through changes in pulmonary circulation, right ventricular function, and fluid balance, factors like mechanical ventilation, hypoxemia, hypercapnia, and systemic inflammation also contribute to kidney dysfunction [30].

Fluid overload is common in ARDS patients and can raise pressure in the right heart chambers, worsening venous congestion and pulmonary hypertension, particularly in cases of severe hypoxia [31]. This increased systemic venous pressure leads to elevated renal interstitial and intratubular pressures, reducing renal perfusion and oxygen delivery, ultimately causing AKI. Additionally, fluid overload in the pulmonary microcirculation can exacerbate pulmonary edema and impair gas exchange [31]. Although a conservative fluid resuscitation strategy may reduce ICU stay, striking a balance between avoiding hypovolemia and ensuring adequate tissue perfusion remains challenging [32]. The type of fluid administered can also influence the severity of hydrostatic and inflammatory pressures in ARDS, though the clinical efficacy of hypo-osmolar albumin, suggested by animal studies, remains uncertain [33, 34].

Hypoxemia and hypercapnia further affect renal circulation by inducing pulmonary arterial vasoconstriction and hypertension, leading to venous congestion. Severe pulmonary hypertension can result in acute right ventricular dysfunction (cor pulmonale), which, if untreated, increases the risk of AKI by elevating interstitial and intratubular pressures and reducing renal perfusion [31].

The use of high positive end-expiratory pressure (PEEP) in mechanical ventilation also increases the risk of AKI in ARDS patients by diminishing renal perfusion due to its hemodynamic effects [29].

The impact of AKI on the lungs

Acute kidney injury triggers significant damage to the tubular epithelium, leading to cell death and the release of inflammatory mediators and oxidative stress, which can adversely affect distant organs, including the lungs [19]. The lungs, with their extensive capillary network, are particularly vulnerable to the systemic effects of AKI, such as increased cytokine production, disrupted nitric oxide metabolism, leukocyte infiltration, and increased pulmonary vascular permeability. Additionally, AKI reduces the expression of critical components like epithelial sodium channels, sodium–potassium adenosine triphosphatase (ATPase), and aquaporin 5, all of which are vital for efficient alveolar fluid clearance.

Experimental studies have highlighted other factors contributing to this pathophysiology, including the systemic release of damage-associated molecular patterns (DAMPs) from necrotic renal cells, caspase-dependent apoptotic pulmonary cell death mediated by TNF-α receptors, and microvascular dysfunction of the alveolar-capillary barrier [35, 36]. The complex interplay between the lung and kidney is exemplified by the use of furosemide, a diuretic that inhibits sodium–potassium-chloride cotransporters. This action not only prevents the secretion of alveolar fluids, alleviating pulmonary edema, but also demonstrates the intricate connection between these organs, as the drug's effects on the lungs occur even before increased diuresis is observed [37].

Therapeutic interventions

The complex interplay between kidney and lung highlights the need for integrated therapeutic strategies, particularly in conditions like AKI and ARDS. Dysfunction in one organ can precipitate pathology in the other, driven by systemic inflammation, hemodynamic changes, and shared pathogenic pathways. Understanding this bidirectional crosstalk is crucial for improving patient outcomes.

Mechanical ventilation

The impact of mechanical ventilation on renal function through hemodynamic impairment

While mechanical ventilation is essential for critically ill patients, it can adversely affect renal function, particularly through hemodynamic impairment [18, 38]. Positive pressure ventilation, unlike spontaneous breathing, maintains pressure throughout the respiratory cycle, which can reduce GFR by influencing airway pressure, tidal volume, and patient volume status [39]. Elevated PEEP has been linked to decreased renal blood flow and GFR. On the other hand, assisted breathing, which activates the diaphragm, can improve renal function and electrolyte balance, reflecting the physiological differences from controlled ventilation [40].

Increased intrathoracic pressure from mechanical ventilation can impair right ventricular function and elevate pulmonary resistance, leading to renal congestion [41]. This congestion arises from increased central venous pressure, reduced arteriovenous gradient within the kidney, and diminished renal blood flow, ultimately causing renal venous hypertension and potential parenchymal congestion. These effects can lead to local hypoxia due to reduced capillary blood flow, exacerbating kidney dysfunction [42].

Intra-abdominal pressure, influenced by diaphragmatic contraction and abdominal compartment characteristics, also affects renal perfusion [43]. Mechanical ventilation can exacerbate this pressure, compromising renal microvascular blood flow, depending on airway and baseline abdominal pressures. The resulting renal edema can perpetuate a cycle of intra-abdominal pressure elevation, further impairing kidney function.

A restrictive fluid strategy is often employed in managing critically ill patients to improve lung injury outcomes. However, in hypovolemic patients, particularly those on positive pressure ventilation, this can deteriorate renal perfusion, increasing the risk of AKI [44].

The impact of mechanical ventilation on renal function through neurohormonal regulation

Mechanical ventilation impacts renal function through neurohormonal regulation. Atrial natriuretic peptide (ANP) responds to fluid balance changes by promoting fluid excretion and influencing renal blood flow. The renin–angiotensin–aldosterone system (RAAS), activated by reduced renal perfusion, produces angiotensin II and aldosterone, leading to vasoconstriction and fluid retention, which alter renal blood flow. Elevated antidiuretic hormone (ADH) levels promote water reabsorption but may be less effective if mechanical ventilation compromises cardiac output. Sympathetic nervous system (SNS) activation also causes renal vasoconstriction, further impacting blood flow. These interactions illustrate the intricate physiological relationship between mechanical ventilation and renal perfusion [45–47] (Fig. 1).Fig. 1 Mechanical ventilation can affect renal blood flow through several interconnected mechanisms. ADH, antidiuretic hormone (also known as vasopressin); ANP atrial natriuretic peptide, RAAS renin–angiotensin–aldosterone system, RBF renal blood flow, SNS sympathetic nervous system

The impact of mechanical ventilation on renal function through the release of biomarkers

Non-protective mechanical ventilation strategies can lead to the release of pro-inflammatory mediators (e.g., TNF-α, IL-1β, IL-6, and IL-8) from alveolar cells, making the kidneys particularly vulnerable to injury [48, 49]. This can result in renal epithelial cell apoptosis, changes in plasma creatinine levels, and alterations in vasoactive mediators, coagulation, and fibrinolysis, alongside factors like vascular endothelial growth factor [50–52].

The RAAS, activated by mechanical ventilation, plays a crucial role in developing acute lung injury and ARDS [53]. While ACE catalyzes the conversion of angiotensin I to angiotensin II, ACE2 counteracts angiotensin II, serving as a negative regulator of the system. The significance of ACE2 became evident during the COVID-19 pandemic [54], where SARS-CoV-2 used ACE2 as its primary receptor to infect lung cells, disrupting the RAAS pathway and leading to uncontrolled angiotensin II elevation, associated with severe disease forms.

In chronic kidney disease (CKD), RAAS inhibitors have effectively slowed disease progression [55, 56], highlighting the RAAS's role in transitioning from AKI to CKD. Recent studies show that blocking renin–angiotensin signaling can reduce CKD development and associated mortality following AKI [57]. Kidney dysfunction can worsen lung edema and impair lung function, with elevated levels of ACE, angiotensin II, and AT1R playing a key role in this process [53].

Extracorporeal therapies

ECMO and continuous RRT (CRRT) provide significant benefits in managing severe ARDS and AKI that are refractory to conventional treatments. ECMO can provide respiratory support while mitigating the deleterious effects of mechanical ventilation on the kidneys, and CRRT can aid in fluid balance and the removal of inflammatory mediators, supporting lung function [58].

Crosstalk between renal support therapies and extracorporeal membrane oxygenation

The incidence of AKI in patients requiring ECMO exceeds 70% and approximately 50% also need renal replacement therapy [29]. Patients with AKI, compared with those without, often experience prolonged mechanical ventilation, extended ECMO support, and higher mortality rates [30].

The primary mechanisms attributed to renal injury during and after ECMO include hypoperfusion, prolonged hypoxemia, ischemia–reperfusion injury after initiation of ECMO, monophasic flow in veno-arterial ECMO, and improper cannula positioning leading to venous or arterial obstruction or platelet disruption resulting in fat embolism [59]. Hemolysis is also a potential complication during extracorporeal therapy, yielding erythrocyte fragmentation due to mechanical stress within the extracorporeal system, air–fluid interface, and excessive negative pressure. This can occur, for instance, with poorly flowing cannulas or in hypovolemic patients [59].

Exposure of blood to the extracorporeal circuit can induce a state of hypercoagulability, resulting in microvascular dysfunction and endothelial damage, ultimately leading to reduced tissue oxygen supply [21]. Along with endothelial dysfunction and consumption of coagulation factors, the use of anticoagulants required for surgeries increases the risk of bleeding, which can affect the outcomes of these patients [21].

Patients undergoing extracorporeal therapies are more sensitive to extremes in fluid balance because both fluid overload and dehydration can impair cardiac, renal, and pulmonary function. Initiation of ECMO can lead to hemodynamic fluctuations due to membrane biocompatibility, leading to AKI through mechanisms of ischemia–reperfusion injury. Furthermore, previously undiagnosed hypovolemia at the time of cannulation can exacerbate renal injury if not promptly addressed.

Similarly, fluid accumulation can have deleterious effects on critically ill patients, potentially accumulating in the interstitium, which exacerbates oxygen impairment, and further reduces glomerular filtration due to congestive syndrome. Veno-arterial ECMO affects hemodynamics differently from veno-venous ECMO. Veno-venous ECMO maintains the pulsatile flow of cardiac output with less impact on renal blood flow. In veno-arterial ECMO, there is a mix of pulsatile flow generated by the heart and non-pulsatile flow generated by ECMO propulsion. Furthermore, the flow in veno-arterial ECMO bypasses the lungs, increasing the risk of embolization, which, combined with the non-pulsatile flow, results in a higher risk of vascular occlusion. Other adverse effects of this laminar flow include changes in endothelial integrity, thus favoring the formation of edema [60], increased RAAS activity, and consequently, reduced renal blood flow [61].

However, when veno-venous ECMO (VV-ECMO) is used to control refractory hypoxemia and/or hypercapnia, it can help mitigate some of the pathophysiological mechanisms contributing to AKI. By improving oxygenation and reducing carbon dioxide levels, VV-ECMO can enhance renal perfusion and alleviate cor pulmonale. Additionally, it enables the use of lung-protective mechanical ventilation strategies.

Therefore, controlling the hemodynamic and mechanical effects of veno-venous ECMO can have a benefit of ECMO in controlling the causative factors of AKI in this population [62]. Hence, renal function must be monitored in patients requiring ECMO because they are at a higher risk of AKI and, consequently, a higher risk of mortality [21].

Integration of ECMO and CRRT

Integration of ECMO and CRRT poses a significant challenge in patients requiring both therapies simultaneously, necessitating careful consideration to prevent potential complications. The primary concerns revolve around bleeding, embolism, coagulation, and hemolysis.

Two integration approaches exist: parallel and series connections, each with its own set of advantages and drawbacks. In parallel connection, the procedures operate independently with separate vascular access points, mitigating risks of embolism, coagulation, and hemolysis. However, the need for additional vascular access raises concerns in critically ill patients already requiring multiple access points and anticoagulation, potentially increasing the risk of iatrogenic complications.

One major challenge in integration is reconciling the significantly different flows and pressures required by each system. ECMO typically necessitates blood flows of 70 to 80 ml/kg/min for adequate oxygenation, while CRRT operates at much lower blood flows of 100 to 150 ml/min. CRRT equipment is designed to function safely at lower pressures than those encountered in the ECMO circuit. In a series connection, the challenge lies in coupling the CRRT machine to an ECMO site with pressure compatible for CRRT operation without exacerbating risks of embolization and coagulation. Safe connection sites include the pre-pump territory of ECMO (negative pressure) and the zone between the ECMO blood pump and the oxygenator, while the post-oxygenator territory is discouraged due to the increased risk of embolization. Pressure disparities between systems elevate the risk of turbulence, hemolysis, frequent interruptions in the CRRT system, and subsequent circuit coagulation (Fig. 2).Fig. 2 Types of extracorporeal membrane oxygenation and continuous renal replacement therapy connection: advantages and disadvantages. A Parallel connection; B series connection

Despite these challenges, series connection offers the advantage of requiring access only for ECMO, minimizing the risks associated with multiple punctures and anticoagulation. Therefore, the optimal integration method depends on the patient's clinical condition and the expertise of the healthcare team.

Mesenchymal stem cell therapy and the crosstalk between lung and kidneys

Mesenchymal stem cells (MSCs) have garnered considerable attention for their regenerative potential and their role in mediating organ repair. Recent research underscores their significance in the context of inter-organ crosstalk, particularly between the kidneys [63] and lungs [64]. MSC therapeutic efficacy is largely attributed to their immunomodulatory properties, ability to promote tissue repair, and capacity to secrete EVs that carry cytokines, growth factors, and genetic material capable of influencing distant tissues. MSCs have been shown to attenuate systemic inflammation, promote tissue repair and regeneration, and may also impact hemodynamic and neurohormonal regulation by modulating the systemic response to organ injury in ARDS [65] and AKI [66]. The application of MSCs therapy in clinical settings holds significant promise for treating diseases involving lung–kidney interactions.

The role of extracellular vesicles in the crosstalk between lung and kidneys

EVs are membrane-bound structures devoid of a nucleus, facilitating vital intercellular communication by transferring diverse biological cargoes, such as proteins, messenger ribonucleic acid (mRNA), and microRNA, between different cell types. While robust evidence is still evolving, the biological plausibility of EVs in mediating organ communication in response to damage is evident [10, 58].

EVs are likely to participate in exchanging harmful mediators between the kidney and lungs through endocrine actions, while also engaging in protective measures to mitigate damage, as observed in models of trauma and hemorrhagic shock [67]. Additionally, EVs hold therapeutic promise in modulating various pathogenic mechanisms underlying organ crosstalk, including endothelial dysfunction, thrombo-inflammation, oxidative stress, and macrophage phenotypic changes [9]. The interplay between EVs from renal tubular epithelial cells and neighboring macrophages, as well as between lung epithelial cells and alveolar macrophages, constitutes a significant mechanism underlying injury in AKI and ARDS, respectively. The potential to attenuate this process using mesenchymal stromal cell-derived EVs or employing epithelial-derived or endothelial-derived EVs to shield endothelial cells from lipopolysaccharide (LPS)-induced permeability holds promise as an etiopathogenetic treatment approach [10, 68].

Moreover, the immunomodulatory properties of EVs extend beyond local damage mechanisms, potentially influencing distant organ crosstalk and inflammatory dysregulation, characteristic of conditions such as sepsis. Future clinical studies should focus on essential aspects that facilitate the broader implementation of EV-based therapy [10, 68].

Other therapies

Anti-inflammatory therapies

Targeting the inflammatory cascade is pivotal in mitigating the crosstalk between AKI and ARDS. Therapies, such as corticosteroids, cytokine inhibitors, and novel anti-inflammatory agents, can potentially reduce systemic inflammation and protect both renal and pulmonary function [69].

Biomarker-Guided Therapies

The identification and the utilization of biomarkers specific to kidney–lung crosstalk can facilitate early diagnosis and tailored interventions. Biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-6 (IL-6), may guide therapeutic decisions and monitor response to treatment [70].

New perspectives and future directions

The evolving understanding of kidney–lung crosstalk opens new avenues for research and therapeutic innovation. EVs, carrying proteins, lipids, and nucleic acids, could serve as novel therapeutic targets or biomarkers for early detection and intervention in AKI and ARDS.

Regenerative medicine also holds potential, with MSCs offering anti-inflammatory and regenerative properties that could be harnessed to repair and protect both renal and pulmonary tissues. Clinical trials are needed to establish optimal dosing regimens, delivery methods, and patient selection criteria. Moreover, ongoing research into the mechanisms underlying MSC-mediated effects on organ interactions will be critical for refining therapeutic approaches and maximizing their efficacy.

Conclusions

The crosstalk between the lungs and kidneys represents a dynamic and bidirectional communication system essential for maintaining physiological homeostasis. This intricate interplay involves a variety of mechanisms and pathways that enable coordinated responses to changes in the internal environment and external stressors. One aspect of lung–kidney crosstalk involves immunological factors, fluid and electrolyte balance, hemodynamic interactions, neurohormonal responses, inflammatory mediators (key signaling molecules in lung–kidney crosstalk), and therapeutic interventions. Understanding the complexities of lung–kidney crosstalk is crucial for optimizing the management of patients with respiratory and renal conditions. This holistic perspective underscores the interconnectedness of these vital organ systems and highlights the importance of integrated therapeutic approaches in critical care medicine.

Take-home message

Understanding the lung–kidney interplay is essential in managing critically ill patients. This review highlights the relationship between ARDS and AKI, where inflammatory mediators contribute to organ damage.

Renal replacement therapy (RRT) can reduce pulmonary edema but carries risks of hemodynamic instability, inflammation, and infection. AKI is common in patients requiring ECMO, leading to prolonged mechanical ventilation and higher mortality rates.

Tweet

Exploring the intricate interplay between lungs & kidneys, and their essential roles in maintaining the body's homeostasis. #Health #Medicine #LungKidneycrosstalk.

Abbreviations

ADH Antidiuretic hormone

AKI Acute kidney injury

Anti-GBM Anti-glomerular basement membrane

ARDS Acute respiratory distress syndrome

CKD Chronic kidney disease

COPD Chronic obstructive pulmonary disease;

CRRT Continuous renal replacement therapy

ECMO Extracorporeal membrane oxygenation

HLA Human leukocyte antigen

ICU Intensive care unit

NO Nitric oxide

PaCO2 Arterial partial pressure of carbon dioxide

PEEP Positive end-expiratory pressure

RAAS Renin–angiotensin–aldosterone system

SIADH Syndrome of inappropriate antidiuretic hormone secretion

Acknowledgements

The authors acknowledge Mrs. Moira Elizabeth Schottler and Ms. Lorna O’Brien (authorserv.com) for their assistance in editing the manuscript.

Author contributions

RSM and PRMR wrote the main manuscript text as well as prepared figures. All authors approved the final version of the manuscript.

Funding

This study was supported by the Brazilian Council for Scientific and Technological Development (CNPq) 443824/2018-5, 403485/2020-7, 408124/2021-0, the Rio de Janeiro, State Research Foundation (FAPERJ) E-26/010.001488/2019, and National Institute of Science and Technology for Regenerative Medicine 465656/2014-5.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publications

Not applicable.

Competing interests

DB is an associate editor of ICMx. The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mrozek S Constantin JM Geeraerts T Brain-lung crosstalk: implications for neurocritical care patients World J Crit Care Med 2015 4 163 178 10.5492/wjccm.v4.i3.163 26261769
Mrozek S, Constantin JM, Geeraerts T (2015) Brain-lung crosstalk: implications for neurocritical care patients. World J Crit Care Med 4:163–17826261769
2. Battaglini D De Rosa S Godoy DA Crosstalk between the nervous system and systemic organs in acute brain injury Neurocrit Care 2024 40 337 348 10.1007/s12028-023-01725-1 37081275
Battaglini D, De Rosa S, Godoy DA (2024) Crosstalk between the nervous system and systemic organs in acute brain injury. Neurocrit Care 40:337–34837081275
3. Reggiani F L'Imperio V Calatroni M Goodpasture syndrome and anti-glomerular basement membrane disease Clin Exp Rheumatol 2023 41 964 974 36995324
Reggiani F, L’Imperio V, Calatroni M et al (2023) Goodpasture syndrome and anti-glomerular basement membrane disease. Clin Exp Rheumatol 41:964–97436995324
4. Rose CE Jr Anderson RJ Carey RM Antidiuresis and vasopressin release with hypoxemia and hypercapnia in conscious dogs Am J Physiol 1984 247 R127 134 6742223
Rose CE Jr, Anderson RJ, Carey RM (1984) Antidiuresis and vasopressin release with hypoxemia and hypercapnia in conscious dogs. Am J Physiol 247:R127-1346742223
5. Sun XJ Li ZY Chen M Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis Rheumatol Immunol Res 2023 4 11 21 10.2478/rir-2023-0003 37138650
Sun XJ, Li ZY, Chen M (2023) Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Immunol Res 4:11–2137138650
6. Sharkey RA Mulloy EM O'Neill SJ The acute effects of oxygen and carbon dioxide on renal vascular resistance in patients with an acute exacerbation of COPD Chest 1999 115 1588 1592 10.1378/chest.115.6.1588 10378553
Sharkey RA, Mulloy EM, O’Neill SJ (1999) The acute effects of oxygen and carbon dioxide on renal vascular resistance in patients with an acute exacerbation of COPD. Chest 115:1588–159210378553
7. Husain-Syed F Slutsky AS Ronco C Lung-kidney cross-talk in the critically ill patient Am J Respir Crit Care Med 2016 194 402 414 10.1164/rccm.201602-0420CP 27337068
Husain-Syed F, Slutsky AS, Ronco C (2016) Lung-kidney cross-talk in the critically ill patient. Am J Respir Crit Care Med 194:402–41427337068
8. Ko GJ Rabb H Hassoun HT Kidney-lung crosstalk in the critically ill patient Blood Purif 2009 28 75 83 10.1159/000218087 19439927
Ko GJ, Rabb H, Hassoun HT (2009) Kidney-lung crosstalk in the critically ill patient. Blood Purif 28:75–8319439927
9. Quaglia M Fanelli V Merlotti G Dual role of extracellular vesicles in sepsis-associated kidney and lung injury Biomedicines 2022 10 2448 10.3390/biomedicines10102448 36289710
Quaglia M, Fanelli V, Merlotti G et al (2022) Dual role of extracellular vesicles in sepsis-associated kidney and lung injury. Biomedicines 10:244836289710
10. Dos Santos CC Lopes-Pacheco M English K The MSC-EV-microRNAome: a perspective on therapeutic mechanisms of action in sepsis and ARDS Cells 2024 13 122 10.3390/cells13020122 38247814
Dos Santos CC, Lopes-Pacheco M, English K et al (2024) The MSC-EV-microRNAome: a perspective on therapeutic mechanisms of action in sepsis and ARDS. Cells 13:12238247814
11. Doyle J, Cooper JS: Physiology, Carbon Dioxide Transport. In: StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jeffrey Cooper declares no relevant financial relationships with ineligible companies.; 2024.
12. Agarwal AK (2021) Iron metabolism and management: focus on chronic kidney disease Kidney Int Suppl 2011 11 46 58 10.1016/j.kisu.2020.12.003
Agarwal AK (2011) (2021) Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl 11:46–58
13. Phelps RG Rees AJ The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity Kidney Int 1999 56 1638 1653 10.1046/j.1523-1755.1999.00720.x 10571772
Phelps RG, Rees AJ (1999) The HLA complex in Goodpasture’s disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 56:1638–165310571772
14. Ahmed M Mohamed S Alhussein H COVID-19 Vaccine as a Potential Triggering Factor for Anti-Glomerular Basement Membrane (GBM) Disease: A Case Report and Literature Review Cureus 2022 14 e29075 36258941
Ahmed M, Mohamed S, Alhussein H et al (2022) COVID-19 Vaccine as a Potential Triggering Factor for Anti-Glomerular Basement Membrane (GBM) Disease: A Case Report and Literature Review. Cureus 14:e2907536258941
15. Proczka M Przybylski J Cudnoch-Jedrzejewska A Vasopressin and Breathing: Review of Evidence for Respiratory Effects of the Antidiuretic Hormone Front Physiol 2021 12 744177 10.3389/fphys.2021.744177 34867449
Proczka M, Przybylski J, Cudnoch-Jedrzejewska A et al (2021) Vasopressin and Breathing: Review of Evidence for Respiratory Effects of the Antidiuretic Hormone. Front Physiol 12:74417734867449
16. Ramadoss J Stewart RH Cudd TA Acute renal response to rapid onset respiratory acidosis Can J Physiol Pharmacol 2011 89 227 231 10.1139/Y11-008 21423296
Ramadoss J, Stewart RH, Cudd TA (2011) Acute renal response to rapid onset respiratory acidosis. Can J Physiol Pharmacol 89:227–23121423296
17. Madias NE Renal acidification responses to respiratory acid-base disorders J Nephrol 2010 23 Suppl 16 S85 91 21170892
Madias NE (2010) Renal acidification responses to respiratory acid-base disorders. J Nephrol 23(Suppl 16):S85-9121170892
18. Kuiper JW Groeneveld AB Slutsky AS Mechanical ventilation and acute renal failure Crit Care Med 2005 33 1408 1415 10.1097/01.CCM.0000165808.30416.EF 15942363
Kuiper JW, Groeneveld AB, Slutsky AS et al (2005) Mechanical ventilation and acute renal failure. Crit Care Med 33:1408–141515942363
19. Li X Hassoun HT Santora R Organ crosstalk: the role of the kidney Curr Opin Crit Care 2009 15 481 487 10.1097/MCC.0b013e328332f69e 19851101
Li X, Hassoun HT, Santora R et al (2009) Organ crosstalk: the role of the kidney. Curr Opin Crit Care 15:481–48719851101
20. Hickman R Crosier JH Saunders SJ Transhepatic metabolism after end-to-side portacaval shunt in the young pig Surgery 1974 76 601 607 4416696
Hickman R, Crosier JH, Saunders SJ et al (1974) Transhepatic metabolism after end-to-side portacaval shunt in the young pig. Surgery 76:601–6074416696
21. Zangrillo A Landoni G Biondi-Zoccai G A meta-analysis of complications and mortality of extracorporeal membrane oxygenation Crit Care Resusc 2013 15 172 178 23944202
Zangrillo A, Landoni G, Biondi-Zoccai G et al (2013) A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 15:172–17823944202
22. Sharkey RA Mulloy EM O'Neill SJ Acute effects of hypoxaemia, hyperoxaemia and hypercapnia on renal blood flow in normal and renal transplant subjects Eur Respir J 1998 12 653 657 10.1183/09031936.98.12030653 9762795
Sharkey RA, Mulloy EM, O’Neill SJ (1998) Acute effects of hypoxaemia, hyperoxaemia and hypercapnia on renal blood flow in normal and renal transplant subjects. Eur Respir J 12:653–6579762795
23. MacNee W Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two Am J Respir Crit Care Med 1994 150 1158 1168 10.1164/ajrccm.150.4.7921453 7921453
MacNee W (1994) Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 150:1158–11687921453
24. MacNee W Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One Am J Respir Crit Care Med 1994 150 833 852 10.1164/ajrccm.150.3.8087359 8087359
MacNee W (1994) Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 150:833–8528087359
25. Kittle CF Aoki H Brown EB Jr The Role of Ph and Co2 in the Distribution of Blood Flow Surgery 1965 57 139 154 14242041
Kittle CF, Aoki H, Brown EB Jr (1965) The Role of Ph and Co2 in the Distribution of Blood Flow. Surgery 57:139–15414242041
26. Mekontso Dessap A Charron C Devaquet J Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome Intensive Care Med 2009 35 1850 1858 10.1007/s00134-009-1569-2 19652953
Mekontso Dessap A, Charron C, Devaquet J et al (2009) Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med 35:1850–185819652953
27. Kilburn KH Dowell AR Renal function in respiratory failure. Effects of hypoxia, hyperoxia, and hypercapnia Arch Intern Med 1971 127 754 762 10.1001/archinte.1971.00310160232020 5555500
Kilburn KH, Dowell AR (1971) Renal function in respiratory failure. Effects of hypoxia, hyperoxia, and hypercapnia. Arch Intern Med 127:754–7625555500
28. Park BD Faubel S Acute kidney injury and acute respiratory distress syndrome Crit Care Clin 2021 37 835 849 10.1016/j.ccc.2021.05.007 34548136
Park BD, Faubel S (2021) Acute kidney injury and acute respiratory distress syndrome. Crit Care Clin 37:835–84934548136
29. Ottolina D Zazzeron L Trevisi L Acute kidney injury (AKI) in patients with Covid-19 infection is associated with ventilatory management with elevated positive end-expiratory pressure (PEEP) J Nephrol 2022 35 99 111 10.1007/s40620-021-01100-3 34170508
Ottolina D, Zazzeron L, Trevisi L et al (2022) Acute kidney injury (AKI) in patients with Covid-19 infection is associated with ventilatory management with elevated positive end-expiratory pressure (PEEP). J Nephrol 35:99–11134170508
30. Mack LA Rumack CM Johnson ML Ultrasound evaluation of cystic intracranial lesions in the neonate Radiology 1980 137 451 455 10.1148/radiology.137.2.6968920 6968920
Mack LA, Rumack CM, Johnson ML (1980) Ultrasound evaluation of cystic intracranial lesions in the neonate. Radiology 137:451–4556968920
31. Hemlin M Ljungman S Carlson J The effects of hypoxia and hypercapnia on renal and heart function, haemodynamics and plasma hormone levels in stable COPD patients Clin Respir J 2007 1 80 90 10.1111/j.1752-699X.2007.00031.x 20298286
Hemlin M, Ljungman S, Carlson J et al (2007) The effects of hypoxia and hypercapnia on renal and heart function, haemodynamics and plasma hormone levels in stable COPD patients. Clin Respir J 1:80–9020298286
32. Wiedemann HP Wheeler AP Bernard GR Comparison of two fluid-management strategies in acute lung injury N Engl J Med 2006 354 2564 2575 10.1056/NEJMoa062200 16714767
Wiedemann HP, Wheeler AP, Bernard GR et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–257516714767
33. Lee J Corl K Levy MM Fluid Therapy and Acute Respiratory Distress Syndrome Crit Care Clin 2021 37 867 875 10.1016/j.ccc.2021.05.012 34548138
Lee J, Corl K, Levy MM (2021) Fluid Therapy and Acute Respiratory Distress Syndrome. Crit Care Clin 37:867–87534548138
34. Mendes RS Oliveira MV Padilha GA Effects of crystalloid, hyper-oncotic albumin, and iso-oncotic albumin on lung and kidney damage in experimental acute lung injury Respir Res 2019 20 155 10.1186/s12931-019-1115-x 31311539
Mendes RS, Oliveira MV, Padilha GA et al (2019) Effects of crystalloid, hyper-oncotic albumin, and iso-oncotic albumin on lung and kidney damage in experimental acute lung injury. Respir Res 20:15531311539
35. Zhao H Ning J Lemaire A Necroptosis and parthanatos are involved in remote lung injury after receiving ischemic renal allografts in rats Kidney Int 2015 87 738 748 10.1038/ki.2014.388 25517913
Zhao H, Ning J, Lemaire A et al (2015) Necroptosis and parthanatos are involved in remote lung injury after receiving ischemic renal allografts in rats. Kidney Int 87:738–74825517913
36. White LE Cui Y Shelak CM Lung endothelial cell apoptosis during ischemic acute kidney injury Shock 2012 38 320 327 10.1097/SHK.0b013e31826359d0 22777112
White LE, Cui Y, Shelak CM et al (2012) Lung endothelial cell apoptosis during ischemic acute kidney injury. Shock 38:320–32722777112
37. Solymosi EA Kaestle-Gembardt SM Vadasz I Chloride transport-driven alveolar fluid secretion is a major contributor to cardiogenic lung edema Proc Natl Acad Sci U S A 2013 110 E2308 2316 10.1073/pnas.1216382110 23645634
Solymosi EA, Kaestle-Gembardt SM, Vadasz I et al (2013) Chloride transport-driven alveolar fluid secretion is a major contributor to cardiogenic lung edema. Proc Natl Acad Sci U S A 110:E2308-231623645634
38. Vieira JM Jr Castro I Curvello-Neto A Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients Crit Care Med 2007 35 184 191 10.1097/01.CCM.0000249828.81705.65 17080002
Vieira JM Jr, Castro I, Curvello-Neto A et al (2007) Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients. Crit Care Med 35:184–19117080002
39. Pinsky MR Cardiovascular issues in respiratory care Chest 2005 128 592S 597S 10.1378/chest.128.5_suppl_2.592S 16306058
Pinsky MR (2005) Cardiovascular issues in respiratory care. Chest 128:592S-597S16306058
40. Steinhoff H Falke K Schwarzhoff W Enhanced renal function associated with intermittent mandatory ventilation in acute respiratory failure Intensive Care Med 1982 8 69 74 10.1007/BF01694869 7076977
Steinhoff H, Falke K, Schwarzhoff W (1982) Enhanced renal function associated with intermittent mandatory ventilation in acute respiratory failure. Intensive Care Med 8:69–747076977
41. Jardin F Delorme G Hardy A Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation Anesthesiology 1990 72 966 970 10.1097/00000542-199006000-00003 2190501
Jardin F, Delorme G, Hardy A et al (1990) Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation. Anesthesiology 72:966–9702190501
42. Gottschalk CW Mylle M Micropuncture study of pressures in proximal tubules and peritubular capillaries of the rat kidney and their relation to ureteral and renal venous pressures Am J Physiol 1956 185 430 439 10.1152/ajplegacy.1956.185.2.430 13327061
Gottschalk CW, Mylle M (1956) Micropuncture study of pressures in proximal tubules and peritubular capillaries of the rat kidney and their relation to ureteral and renal venous pressures. Am J Physiol 185:430–43913327061
43. Verbrugge FH Dupont M Steels P Abdominal contributions to cardiorenal dysfunction in congestive heart failure J Am Coll Cardiol 2013 62 485 495 10.1016/j.jacc.2013.04.070 23747781
Verbrugge FH, Dupont M, Steels P et al (2013) Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 62:485–49523747781
44. Griffiths M Fan E Baudouin SV New UK guidelines for the management of adult patients with ARDS Thorax 2019 74 931 933 10.1136/thoraxjnl-2018-212885 31481634
Griffiths M, Fan E, Baudouin SV (2019) New UK guidelines for the management of adult patients with ARDS. Thorax 74:931–93331481634
45. Pannu N Mehta RL Effect of mechanical ventilation on the kidney Best Pract Res Clin Anaesthesiol 2004 18 189 203 10.1016/j.bpa.2003.08.002 14760882
Pannu N, Mehta RL (2004) Effect of mechanical ventilation on the kidney. Best Pract Res Clin Anaesthesiol 18:189–20314760882
46. Annat G Viale JP Bui Xuan B Effect of PEEP ventilation on renal function, plasma renin, aldosterone, neurophysins and urinary ADH, and prostaglandins Anesthesiology 1983 58 136 141 10.1097/00000542-198302000-00006 6337527
Annat G, Viale JP, Bui Xuan B et al (1983) Effect of PEEP ventilation on renal function, plasma renin, aldosterone, neurophysins and urinary ADH, and prostaglandins. Anesthesiology 58:136–1416337527
47. Farge D De la Coussaye JE Beloucif S Interactions between hemodynamic and hormonal modifications during PEEP-induced antidiuresis and antinatriuresis Chest 1995 107 1095 1100 10.1378/chest.107.4.1095 7705122
Farge D, De la Coussaye JE, Beloucif S et al (1995) Interactions between hemodynamic and hormonal modifications during PEEP-induced antidiuresis and antinatriuresis. Chest 107:1095–11007705122
48. Bellani G Laffey JG Pham T Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries JAMA 2016 315 788 800 10.1001/jama.2016.0291 26903337
Bellani G, Laffey JG, Pham T et al (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:788–80026903337
49. Slutsky AS Ranieri VM Ventilator-induced lung injury N Engl J Med 2013 369 2126 2136 10.1056/NEJMra1208707 24283226
Slutsky AS, Ranieri VM (2013) Ventilator-induced lung injury. N Engl J Med 369:2126–213624283226
50. Imai Y Parodo J Kajikawa O Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome JAMA 2003 289 2104 2112 10.1001/jama.289.16.2104 12709468
Imai Y, Parodo J, Kajikawa O et al (2003) Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 289:2104–211212709468
51. Kuiper JW Versteilen AM Niessen HW Production of endothelin-1 and reduced blood flow in the rat kidney during lung-injurious mechanical ventilation Anesth Analg 2008 107 1276 1283 10.1213/ane.0b013e31818067a2 18806040
Kuiper JW, Versteilen AM, Niessen HW et al (2008) Production of endothelin-1 and reduced blood flow in the rat kidney during lung-injurious mechanical ventilation. Anesth Analg 107:1276–128318806040
52. Haitsma JJ Schultz MJ Hofstra JJ Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia Eur Respir J 2008 32 1599 1606 10.1183/09031936.00045908 18768578
Haitsma JJ, Schultz MJ, Hofstra JJ et al (2008) Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Eur Respir J 32:1599–160618768578
53. Imai Y Kuba K Rao S Angiotensin-converting enzyme 2 protects from severe acute lung failure Nature 2005 436 112 116 10.1038/nature03712 16001071
Imai Y, Kuba K, Rao S et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:112–11616001071
54. Lopes-Pacheco M Silva PL Cruz FF Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies Front Physiol 2021 12 593223 10.3389/fphys.2021.593223 33584343
Lopes-Pacheco M, Silva PL, Cruz FF et al (2021) Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol 12:59322333584343
55. Ruggenenti P Perna A Remuzzi G ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy J Am Soc Nephrol 2001 12 2832 2837 10.1681/ASN.V12122832 11729254
Ruggenenti P, Perna A, Remuzzi G (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12:2832–283711729254
56. Remuzzi G Ruggenenti P Perna A Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results J Am Soc Nephrol 2004 15 3117 3125 10.1097/01.ASN.0000146423.71226.0C 15579515
Remuzzi G, Ruggenenti P, Perna A et al (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15:3117–312515579515
57. Rodriguez-Romo R Benitez K Barrera-Chimal J AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease Kidney Int 2016 89 363 373 10.1038/ki.2015.320 26509589
Rodriguez-Romo R, Benitez K, Barrera-Chimal J et al (2016) AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease. Kidney Int 89:363–37326509589
58. Raja M Leal R Doyle J Continuous renal replacement therapy in patients receiving extracorporeal membrane oxygenation therapy J Intensive Care Soc 2023 24 227 229 10.1177/17511437211067088 37260434
Raja M, Leal R, Doyle J (2023) Continuous renal replacement therapy in patients receiving extracorporeal membrane oxygenation therapy. J Intensive Care Soc 24:227–22937260434
59. Chen H Yu RG Yin NN Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review Crit Care 2014 18 675 10.1186/s13054-014-0675-x 25482187
Chen H, Yu RG, Yin NN et al (2014) Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review. Crit Care 18:67525482187
60. Orime Y Shiono M Hata H Cytokine and endothelial damage in pulsatile and nonpulsatile cardiopulmonary bypass Artif Organs 1999 23 508 512 10.1046/j.1525-1594.1999.06392.x 10392275
Orime Y, Shiono M, Hata H et al (1999) Cytokine and endothelial damage in pulsatile and nonpulsatile cardiopulmonary bypass. Artif Organs 23:508–51210392275
61. Lombardi G Gambaro A Ribichini FL RAS inhibitors and renal and general mortality in patients with heart failure supported by left ventricular assist devices: a registry study Clin Res Cardiol 2023 112 891 900 10.1007/s00392-022-02136-6 36459185
Lombardi G, Gambaro A, Ribichini FL et al (2023) RAS inhibitors and renal and general mortality in patients with heart failure supported by left ventricular assist devices: a registry study. Clin Res Cardiol 112:891–90036459185
62. Mucino-Bermejo MJ Extracorporeal organ support and the kidney Front Nephrol 2022 2 924363 10.3389/fneph.2022.924363 37674997
Mucino-Bermejo MJ (2022) Extracorporeal organ support and the kidney. Front Nephrol 2:92436337674997
63. Tetta C Deregibus MC Camussi G Stem cells and stem cell-derived extracellular vesicles in acute and chronic kidney diseases: mechanisms of repair Ann Transl Med 2020 8 570 10.21037/atm.2020.03.19 32775371
Tetta C, Deregibus MC, Camussi G (2020) Stem cells and stem cell-derived extracellular vesicles in acute and chronic kidney diseases: mechanisms of repair. Ann Transl Med 8:57032775371
64. Xiao K Hou F Huang X Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Stem Cell Res Ther 2020 11 305 10.1186/s13287-020-01804-6 32698898
Xiao K, Hou F, Huang X et al (2020) Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res Ther 11:30532698898
65. Qin H Zhao A Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics Protein Cell 2020 11 707 722 10.1007/s13238-020-00738-2 32519302
Qin H, Zhao A (2020) Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell 11:707–72232519302
66. Humphreys BD Bonventre JV Mesenchymal stem cells in acute kidney injury Annu Rev Med 2008 59 311 325 10.1146/annurev.med.59.061506.154239 17914926
Humphreys BD, Bonventre JV (2008) Mesenchymal stem cells in acute kidney injury. Annu Rev Med 59:311–32517914926
67. Kerr NA de Rivero Vaccari JP Abbassi S Traumatic brain injury-induced acute lung injury: evidence for activation and inhibition of a neural-respiratory-inflammasome axis J Neurotrauma 2018 35 2067 2076 10.1089/neu.2017.5430 29648974
Kerr NA, de Rivero Vaccari JP, Abbassi S et al (2018) Traumatic brain injury-induced acute lung injury: evidence for activation and inhibition of a neural-respiratory-inflammasome axis. J Neurotrauma 35:2067–207629648974
68. Abreu SC Lopes-Pacheco M Weiss DJ Mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and perspectives Front Cell Dev Biol 2021 9 600711 10.3389/fcell.2021.600711 33659247
Abreu SC, Lopes-Pacheco M, Weiss DJ et al (2021) Mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and perspectives. Front Cell Dev Biol 9:60071133659247
69. Malek M Hassanshahi J Fartootzadeh R Nephrogenic acute respiratory distress syndrome: a narrative review on pathophysiology and treatment Chin J Traumatol 2018 21 4 10 10.1016/j.cjtee.2017.07.004 29398292
Malek M, Hassanshahi J, Fartootzadeh R et al (2018) Nephrogenic acute respiratory distress syndrome: a narrative review on pathophysiology and treatment. Chin J Traumatol 21:4–1029398292
70. Komaru Y Oguchi M Sadahiro T Urinary neutrophil gelatinase-associated lipocalin and plasma IL-6 in discontinuation of continuous venovenous hemodiafiltration for severe acute kidney injury: a multicenter prospective observational study Ann Intensive Care 2023 13 42 10.1186/s13613-023-01137-6 37184598
Komaru Y, Oguchi M, Sadahiro T et al (2023) Urinary neutrophil gelatinase-associated lipocalin and plasma IL-6 in discontinuation of continuous venovenous hemodiafiltration for severe acute kidney injury: a multicenter prospective observational study. Ann Intensive Care 13:4237184598
